As infectious agents, viruses are a cause of significant health problem world-wide, especially in the developing nations. Infection of viruses could lead to various human diseases such as influenza, AIDS and cancers. With the development of technology, use of next generation sequencing to study globally relevant viral infections have revolutionized our understanding of the within host and between host evolution of these viruses.
CD Genomics' HBV/HPV/EBV capture sequencing is designed for target enrichment of different viruses and their subtypes, which is necessary to detect low abundance virus populations, in next generation sequencing (NGS) applications on Illumina ® platforms. This panel platform could effectively help researchers to identify different types or subtypes of viruses, analyze mutations on the viruses and help make treatment strategies, providing a new insight into medical research especially in cancer area.
|Virus Type||Product Description||Suitable Scope|
|HBV||Able to detect HVB subtype A, B, C, D, E, F, G, H and other known subtypes||HBV infected liver cancer or other HBV infection causing disease study|
|HPV||Including 6, 11, 16, 18, 31, 33, 35, 39, 45, 52, 58, 59, 66, 68, 69, 82 and other known subtypes||Cervical cancer and other HPV integration-driven cancer|
|EBV||Whole EBV genome capture||Nasopharynx Cancer, Lymphoma and other EBV infection-caused cancer|
We provide customized bioinformatics analysis including:
CD Genomics provides the accurate and cost-effective HBV/HPV/EBV capture sequencing and bioinformatics analysis. Our professional expert team executes quality management, following every procedure to ensure confident and unbiased results. The general workflow for virus genome capture sequencing is outlined below.
For more information about the HBV/HPV/EBV capture sequencing or need other amplification requirements, please contact us.